Global Radiopharmaceutical CDMO Market Set to Surge to USD 8.50 Billion by 2035 | Booming Demand in Diagnostic & Therapeutic Radiopharmaceuticals
Radiopharmaceutical CDMO Market Forecast to Expand at a 10.12% CAGR Driven by Oncology Growth, Nuclear Medicine Adoption, and Outsourcing Trends
The Global Radiopharmaceutical CDMO Market, a critical backbone of the growing nuclear medicine and personalized therapy ecosystem, is projected to expand from USD 3.24 billion in 2025 to USD 8.50 billion by 2035, registering a robust 10.12% CAGR during the forecast period. Increasing outsourcing of radiopharmaceutical development, regulatory complexity, rising oncology pipelines, and expansion in PET/SPECT imaging are primary factors steering market growth.
Radiopharmaceutical CDMO Market Key Insights
-
The total global market value for Radiopharmaceutical CDMO services reached USD 3.24 billion in 2025 and is on a steep growth trajectory toward USD 8.50 billion by 2035.
-
North America commanded ~49% share of the market in 2025, holding the lead in development and outsourcing.
-
The Asia Pacific region is forecast to be the fastest-growing market through 2035.
-
Diagnostic radiopharmaceuticals dominated segmentation in 2025 with ~62% share reflecting high PET/SPECT imaging volumes.
-
Therapeutic radiopharmaceuticals are growing fastest — backed by surging radioligand therapy pipelines.
-
Contract manufacturing services held the highest share in 2025; whereas packaging and logistics services are the fastest-growing service segment.
-
Oncology applications dominated the therapeutic landscape with 71% share in 2025.
Radiopharmaceutical CDMO Market Revenue Snapshot
| Metric | Value |
|---|---|
| 2025 Market Size | USD 3.24 Billion |
| 2026 Estimate | USD 3.57 Billion |
| 2035 Forecast | USD 8.50 Billion |
| Projected CAGR (2026–2035) | 10.12% |
| Dominating Region (2025) | North America |
| Fastest Growing Region | Asia Pacific |
What Is Driving Radiopharmaceutical CDMO Market Expansion?
Radiopharmaceutical CDMOs are specialized partners enabling pharmaceutical and biotech companies to develop, manufacture, and commercialize radioactive drugs used for diagnostic imaging and targeted cancer therapies. These third-party experts manage everything from isotope handling to regulatory submission and sterile production.
Key market drivers include:
-
Surge in nuclear medicine procedures and theranostic applications.
-
Increasing complexity of radioligand drugs requiring specialized facilities.
-
Outsourcing to reduce capital expenditure and regulatory compliance burdens.
-
Growing clinical development pipeline for diagnostic and therapeutic radiopharmaceuticals.
AI’s Strategic Role in the Radiopharmaceutical CDMO Market
Artificial Intelligence (AI) is becoming a transformative force in radiopharmaceutical contract development and manufacturing operations. By harnessing AI-powered predictive analytics, digital twins, and advanced quality monitoring, CDMOs are achieving accelerated process optimization, reduced human error, and enhanced compliance with strict manufacturing standards.
AI tools are enabling virtual simulation of manufacturing environments, optimizing production schedules, and identifying logistical bottlenecks before they occur — all critical in managing short-half-life radioactive compounds with time-sensitive production needs. Looking ahead, AI integration is set to become a strategic differentiator for CDMOs competing on speed, quality, and regulatory reliability.
Radiopharmaceutical CDMO Market Growth Factors
Several forces are fueling CDMO demand:
1. Regulatory Complexity — Stringent Good Manufacturing Practices (GMP) and radiation safety requirements are driving pharmaceutical firms toward seasoned CDMOs with proven compliance records.
2. Supply Chain Constraints — Limited global isotope availability, especially for Lutetium-177, is spurring collaborations between CDMOs and isotope suppliers to secure stable production pipelines.
3. Localized Production — National healthcare initiatives are boosting domestic radiopharmaceutical manufacturing capacity, reducing dependency on cross-border shipments and decay losses.
What Major Trends Are Shaping the Market?
How is oncology fueling radiopharmaceutical CDMO demand?
Cancer remains the largest therapeutic area in the radiopharmaceutical space, with theranostic radioligand therapies prompting repeated engagements with CDMOs due to drug complexity and personalization needs.
Why is Asia Pacific the fastest-growing market?
Rapid expansion of healthcare infrastructure, rising nuclear medicine uptake, and investment in diagnostic capabilities position the region for accelerated growth through 2035.
What service innovations are gaining traction?
End-to-end packaging, cold-chain logistics, and regulatory support are key differentiators as decentralized imaging and therapy centers demand rapid, reliable delivery.
Radiopharmaceutical CDMO Market Regional Highlights
North America
Dominated the market with nearly half of global share in 2025 due to advanced nuclear medicine ecosystems, extensive collaborations between developers and isotope suppliers, and established regulatory frameworks enabling radiopharmaceutical production.
Europe & Asia-Pacific
Europe shows strong adoption driven by healthcare investments, while Asia-Pacific is fastest-growing as countries expand PET/SPECT infrastructure and therapeutic pipelines.
Latest Breakthroughs & Company Developments
Notable moves include strategic acquisitions and service expansions by leading providers such as:
-
Curium Pharma
-
Eckert & Ziegler
-
ITM Isotope Technologies Munich
-
NorthStar Medical Radioisotopes
-
Cardinal Health
-
SOFIE Biosciences
-
PharmaLogic Holdings
-
SpectronRx
-
SHINE Technologies
-
IONETIX Corporation
-
Nucleus RadioPharma
-
Evergreen Theragnostics
-
Monrol, Seibersdorf Labor GmbH
-
Minerva Imaging
-
Nihon Medi-Physics
Recent innovations include new infusion systems for safer radiopharmaceutical delivery and major manufacturing capacity expansions.
Challenges & Cost Pressures
Despite growth, the market confronts high capital expenditure, isotope supply constraints, and regulatory hurdles — all of which put cost pressure on providers and push developers toward outsourcing to CDMOs with robust infrastructure.
Case Study: Diagnostic Radiopharmaceutical Outsourcing Success
A leading diagnostic firm partnering with a specialized CDMO shifted its short-half-life tracer production entirely to outsourced facilities, reducing time-to-clinic by 30%, optimizing regulatory submissions, and ensuring consistent PET supply across multiple markets — illustrating CDMO value in speed and compliance.
Segments Covered in the Report
By Application
- Diagnostic Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals
By Radioisotope Type
- Fluorine-18
- Technetium-99m
- Gallium-68
- Lutetium-177
- Actinium-225
- Others
By Service Type
- Contract Manufacturing
- Contract Development
- Analytical & Quality Control Services
- Packaging, Labeling & Logistics
By Therapeutic Area
- Oncology
- Neurology (Fastest Growing)
- Cardiology
- Others (Nephrology, Inflammation, Rare Diseases)
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7320
You can place an order or ask any questions. Please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344
- Battery Swapping Market Size to Touch USD 24.74 Billion by 2035 - March 5, 2026
- Dental Air Polishing System Market Size to Reach USD 1603.54 Million by 2035 - March 4, 2026
- Cryoballoon Ablation System Market Size to Surpass USD 2.49 Billion by 2035, Propelled by 5.70% Growth in Minimally Invasive Cardiac Care - March 2, 2026
